Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types including formalin fixed paraffin embedded (FFPE) tissue.
RNA-enrichment provides quantitative expression information as well as the detection of small variants and gene fusions. RNA enrichment offers the following features:
RNA expression panels can be designed to focus on RNA sequences of interest or custom content can be added to fully optimized and experimentally validated panels.
Frank Middleton, Ph.D., at SUNY Upstate Medical University (UMU) developed a focused gene panel to screen for expression alterations caused by a newly discovered CNV in schizophrenia. See why Dr. Middleton used targeted RNA-Seq rather than PCR or arrays to analyze several hundred genes associated with schizophrenia, bipolar disorder, and autism.Read Interview
Illumina sequencing by synthesis (SBS) chemistry is the most widely adopted NGS technology, generating approximately 90% of global sequencing data.*
In addition to our industry-leading sequencing, Illumina offers integrated targeted RNA-Seq workflows that simplify the entire process, from library preparation to data analysis and biological interpretation.
Click on the below to view products for each workflow step.
Highly customizable panels for mid- to high-plex gene expression profiling starting with as little as 50 ng RNA. FFPE RNA compatible.TruSight RNA Pan-Cancer
Targeting 1385 oncology genes for gene expression, variant and fusion detection in many RNA sample types including FFPE.TruSight Tumor 170
Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.
A gene fusion detection panel targeting fusion associated genes in many cancer types with the ability to detect known and novel fusion gene partners.DesignStudio
Easy-to-use, web-based assay design tool. Customize sequencing content to fit the needs of your study.Library Prep Kit Selector Library Prep Kit Selector
Determine the best kit for your needs based on project type, starting material, and method or application.
Targeted Power. Access proven Illumina quality with this small, robust NGS system. Up to 384 targeted RNA samples per run.**MiSeq Series
Focused Power. Speed and simplicity for targeted and small genome sequencing. Up to 384 targeted RNA samples per run.**NextSeq Series
Flexible power. Speed and simplicity for everyday genomics. Up to 384 targeted RNA samples per run.**
Production power. Max throughput and lowest cost for production-scale genomics. Up to 6144 targeted RNA samples per run.**Platform Comparison Tool
Compare sequencing platforms and identify the best system for your lab and applications.Sequencing Reagents
Find kits that include sequencing reagents, flow cells, and buffers tailored to each Illumina sequencing system.
The TruSeq Targeted RNA App is available on MiSeq Reporter and BaseSpace.Local Run Manager
Easy-to-use software for automated on-instrument data analysis.The Broad’s IGV
A genome browser developed by the Broad Institute of MIT and Harvard that displays NGS data for complex variant analysis.Genomatix Pathway System (GePS)
Associates single gene or list of genes with annotation data for pathways, diseases, tissues, and small molecules.
Differential gene expression, drug interaction, and disease analysis.BaseSpace Sequence Hub
The Illumina genomics computing environment for NGS data analysis and management.BaseSpace Correlation Engine
A growing library of curated genomic data to support researchers in identifying disease mechanisms, drug targets, and biomarkers.Local Run Manager
Easy-to-use software for automated on-instrument data analysis.
Monitoring gene expression and transcriptome changes with targeted RNA-Seq can help researchers understand which variants are expressed and which may affect tumorigenesis and progression. Learn more about targeted RNA-Seq in cancer research.
Illumina provides an innovative portfolio of genomic sequencing solutions for all phases of the drug development pipeline. Characterize gene expression profiles from a custom panel with a few defined targets to the whole transcriptome. Learn more about NGS in drug development.
With specifically designed targeted RNA expression panels, neuroscientists can gain insights into whether neurodegenerative and neurotoxic pathways are compromised within study populations. Learn more about neuroscience research.
Find out how to utilize RNA-Seq to profile or discover RNA-based drug response biomarkers. Access resources designed to help new users adopt this application. Learn more about drug response RNA biomarker analysis.
*Data calculations on file. Illumina, Inc., 2015
**Based on TruSeq indexing and up to 65 targets for MiniSeq or MiSeq, 1041 targets for NextSeq 500, and 651 targets/lane for HiSeq.